Who backs Parabilis Medicines?
38 investors| Investor | Type |
|---|---|
| General Catalyst | Venture capital |
| Fidelity Management & Research Company | Asset manager |
| RA Capital Management | Asset manager |
| GV | Venture capital |
| ARCH Venture Partners | Venture capital |
| Catalio Capital Management | Venture capital |
| T. Rowe Price Group | — |
| Horizons Ventures | Venture capital |
| The Invus Group | PE / buyout |
| Foresite Capital | Venture capital |
| + 28 more investors · a free account shows the complete list | |
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns
Membership and data by Private Market View
Parabilis Medicines investors
38 investors are on record for Parabilis Medicines, including General Catalyst, Fidelity Management & Research Company, RA Capital Management and GV. By type, the record holds 14 venture capital firms, 3 hedge funds and 2 private equity firms. The Series F in Jan 2026 drew 21 investors.
Free account
More of Parabilis Medicines with a free account
- ·The complete investor list: 38 names
- ·Watch Parabilis Medicines: the Monday email on marks, rounds and moves
For fundraisers
Work this list, don’t just read it
These 38 firms already write checks for companies like Parabilis Medicines in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.
Membership and data by Private Market View